Tuberculosis Case Management Care Plan

Patient's Name/DOB:	Initial Report (Date/Source):
Nurse Case Manager (NCM):	Licensed Healthcare Provider (LHP):

Directions: Document TB case management activities* for patients with known/suspected drug susceptible TB including the date and initials when a task is completed. The referenced <u>DSHS TB forms</u> contain key information for each activity. Programs may use an alternative form or electronic health record (EHR) template that contains *equivalent* information.

*Refer to the <u>DSHS TB Standing Delegation Orders (SDOs)</u> and the <u>Texas TB Manual</u> for detailed information on these case management activities. Refer to **TB-701** form for documenting case management activities on patients that require a second line drug regimen.

	0	1	2	3	4	5	6 26	9 39	12 52	
Activity	Weeks Details									
Responsibility	Assign NCM and identify LHP and other team members. TB-201									
Consents	General L-36 Acknowledgement of Understanding TB-409 Hurricane Questionnaire TB-209 HIPPA Medical Information Release L-30									
	Obtain before treatment initiation and anytime a drug is added to the regimen. Client/DOT Provider Agreement TB-206									
	Signed monthly by patient and DOT staff. Video-DOT Client Agreement if using VDOT. 12-15762 Indicate when interpreter used.									
Education	Provide initial and ongoing patient education. Document specific education, at minimum monthly. TB-203									

Tuberculosis Case Management Care Plan

	Treatment Months	0	1	2	3	4	5	6	9	12
	Weeks			8				26	39	52
	Medical history and TB symptom screening. TB-202									
	Baseline IGRA or TST testing (unless documented									
	previous positive result).									
	CXRs at baseline, and as indicated.									
	Sputum collection (x 3) at baseline with AFB smear and									
	culture testing:									
	8-24 hours apart;									
	1 observed and 1 morning specimen; and									
	1 specimen with NAA/PCR testing including RIF									
	resistance.									
	Repeat sputum collection if indicated.									
	Drug susceptibility testing (DST) on initial positive <i>M.tb</i>			\checkmark						
	culture.			DSTs						
	HIV testing.									
Clinical	Collect labs at baseline, monthly, as outlined in SDOs and									
Evaluation	per LHP order.									
	LHP reviews case, documents, and signs orders, ideally									
	monthly, but at minimum:									
	before treatment initiation;									
	 before end of intensive phase; 									
	 as needed for clinical concerns; 									
	 at closure: 26 weeks (6-months); and/or 									
	at closure: 39 weeks (9-months).									
	NCM ensures completion of clinical evaluation and toxicity									
	assessment at baseline, monthly, as needed for clinical									
	concerns. TB-205 Include:									
	Snellen visual acuity and Ishihara color									
	discrimination (EMB);									
	peripheral neuropathy (high dose INH); and									
0 11 11	eye assessment (RBT).		<u> </u>							
Consultation	Request a consult when indicated.									
	Drug regimen is approved as per SDOs with correct									
Treatment	weight-based doses. DOT/VDOT medication administration documented. TB-206		-							
	•									
	PZA discontinued after 8 weeks (40-56 DOT doses) and LHP order.									

Tuberculosis Case Management Care Plan

	Treatment Months	0	1	2	3	4	5	6	9	12
	Weeks			8				26	39	52
Treatment (continued)	EMB discontinued after INH and RIF DSTs confirmed and LHP order.									1
Adherence	NCM reviews medication adherence at least weekly; documents interventions for missed DOT or appointments.									<u> </u>
Adherence	Court-ordered management may be pursued after unsuccessful steps to address non-adherence, per TB Manual.									
	Conduct initial CI interview for case/suspect within 3 working days. CI Worksheet 12-12062									
	Visit primary residence of patient within 3 days. Visit other settings where transmission may have occurred (i.e., congregate settings, workplace, dialysis center, long term care facility).									
	Prioritize contacts before initiating contact screening.									
Contact Investigation (CI)	Initiate high priority contact screening within 7 working days. TB-208 Include: • IGRA/ TST test; • TB disease signs and symptoms; • risk factors; and • CXR (if indicated).									
	Provide education and counseling.									
	Consider if CI expansion is warranted. TB-460 Perform second round screening for contacts with negative first round results 8-10 weeks* after: • break in contact or • end of index case's infectious period. Report screening results. TB 340 *See Texas Manual.									
TB Isolation	Initiate and discontinue isolation when indicated.									
Quality Assurance (QA)	Perform routine QA activities per program protocol (e.g., case review, cohort review, CI review).									

Tuberculosis Case Management Care Plan

	Treatment Months Weeks	0	1	2 8	3	4	5	6 26	9 39	12 52
	Evaluate barriers to treatment at baseline; reassess throughout care.									
Patient Centered Care	Medical referrals: Medicare (if eligible), Federal Qualified Health Center (FQHC), drug/alcohol treatment, nutritional support, diabetes education, HIV care, etc.									
	Social services referrals: social work, behavioral health, TB support group, etc.									
	Create NEDSS Investigation within 3 business days of notification.									
Reporting	Reclassify TB suspect (ATS 5) within 90 days.									
(NEDSS)	Update NEDSS Tabs: Patient, Case Info, TB History, Tuberculosis, TB Disease Only, Comprehensive TB Treatment Details, and Contact Investigation.									

Case Management Team:

Name:	In	nitials:	Name:	Initials:	Name:	Initials:
Name:	In	nitials:	Name:	Initials:	Name:	Initials:
Name:	In	nitials:	Name:	Initials:	Name:	Initials: